rh norrin Search Results


rh norrin  (R&D Systems)
93
R&D Systems rh norrin
<t>(A)</t> <t>Noregen</t> FZD4 receptor binding activity compared to <t>Norrin,</t> EC 50 19 ng/mL & 34 ng/mL respectively. (B) Noregen dose response curve for TCF/LEF reporter activation in HEK-293 cells (EC 50 11 ng/mL). (C) Noregen induced Axin-2 gene expression in HRMECs. Values are means +/-SD; *P<0.05, **P<0.01, ***P<0.001 & ****P<0.0001.
Rh Norrin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rh norrin/product/R&D Systems
Average 93 stars, based on 1 article reviews
rh norrin - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier
trypanosoma conorrhini (donovan) shortt and swaminath  (ATCC)
N/A
   Buy from Supplier

Image Search Results


(A) Noregen FZD4 receptor binding activity compared to Norrin, EC 50 19 ng/mL & 34 ng/mL respectively. (B) Noregen dose response curve for TCF/LEF reporter activation in HEK-293 cells (EC 50 11 ng/mL). (C) Noregen induced Axin-2 gene expression in HRMECs. Values are means +/-SD; *P<0.05, **P<0.01, ***P<0.001 & ****P<0.0001.

Journal: bioRxiv

Article Title: A recombinant norrin-derived growth factor retains the complete multifunctionality of human norrin

doi: 10.1101/2025.10.15.682582

Figure Lengend Snippet: (A) Noregen FZD4 receptor binding activity compared to Norrin, EC 50 19 ng/mL & 34 ng/mL respectively. (B) Noregen dose response curve for TCF/LEF reporter activation in HEK-293 cells (EC 50 11 ng/mL). (C) Noregen induced Axin-2 gene expression in HRMECs. Values are means +/-SD; *P<0.05, **P<0.01, ***P<0.001 & ****P<0.0001.

Article Snippet: The cells were weaned to media containing no hydrocortisone hemisuccinate prior to stimulation with Noregen or rh norrin (R&D Systems, Minneapolis MN;3014-NR).

Techniques: Binding Assay, Activity Assay, Activation Assay, Gene Expression

(A) Noregen significantly increases HRMEC proliferation as seen by a drop in capacitance when treated at 20 and 500 ng/mL. (B) Norrin increases proliferation to a similar extent as Noregen at the higher 500 ng/mL treatment level, but to a lesser extent at 20 ng/mL. (C) Comparison of Noregen and norrin treatments at 20 ng/mL. An earlier drop in capacitance indicates faster growth in Noregen treated cells.

Journal: bioRxiv

Article Title: A recombinant norrin-derived growth factor retains the complete multifunctionality of human norrin

doi: 10.1101/2025.10.15.682582

Figure Lengend Snippet: (A) Noregen significantly increases HRMEC proliferation as seen by a drop in capacitance when treated at 20 and 500 ng/mL. (B) Norrin increases proliferation to a similar extent as Noregen at the higher 500 ng/mL treatment level, but to a lesser extent at 20 ng/mL. (C) Comparison of Noregen and norrin treatments at 20 ng/mL. An earlier drop in capacitance indicates faster growth in Noregen treated cells.

Article Snippet: The cells were weaned to media containing no hydrocortisone hemisuccinate prior to stimulation with Noregen or rh norrin (R&D Systems, Minneapolis MN;3014-NR).

Techniques: Comparison

(A) Reduction in normalized avascular area [AVA to Total Area ratio] in Noregen & norrin injected eyes. The [AVA to Total Area ratio] in injected eyes was normalized to fellow un-injected eyes. Noregen levels were 2, 20 or 200 ng. Values are means +/-SEM; *P<0.05, **P<0.01. (B) Dose dependent reduction in normalized avascular area seen when graphing in comparison to averaged Vehicle from combined cohorts. (C) Example retinal flatmount images with AVA highlighted in white. (D) Confocal images of superficial (S), intermediate (I) & deep (D) vascular beds in Noregen(200 ng/eye) and vehicle injected OIR eyes.

Journal: bioRxiv

Article Title: A recombinant norrin-derived growth factor retains the complete multifunctionality of human norrin

doi: 10.1101/2025.10.15.682582

Figure Lengend Snippet: (A) Reduction in normalized avascular area [AVA to Total Area ratio] in Noregen & norrin injected eyes. The [AVA to Total Area ratio] in injected eyes was normalized to fellow un-injected eyes. Noregen levels were 2, 20 or 200 ng. Values are means +/-SEM; *P<0.05, **P<0.01. (B) Dose dependent reduction in normalized avascular area seen when graphing in comparison to averaged Vehicle from combined cohorts. (C) Example retinal flatmount images with AVA highlighted in white. (D) Confocal images of superficial (S), intermediate (I) & deep (D) vascular beds in Noregen(200 ng/eye) and vehicle injected OIR eyes.

Article Snippet: The cells were weaned to media containing no hydrocortisone hemisuccinate prior to stimulation with Noregen or rh norrin (R&D Systems, Minneapolis MN;3014-NR).

Techniques: Injection, Comparison

(A) Diagram illustrating TGF-ß1 and BMP-2 pathways. Norrin inhibits signaling via SMAD7 induction, thereby inhibiting pathway activation. (B) Noregen reduction in basal level and TGF-ß1 induced SMAD reporter activation. Values are means +/-SD; *P<0.05, **P<0.01, ***P<0.001. (C) ZO-1 immunostaining of HRMECs treated with TGF-ß1 or BMP-2 alone (translocation of ZO-1 to cytosol) or in combination with Noregen (restoration of ZO-1 at plasma membrane).

Journal: bioRxiv

Article Title: A recombinant norrin-derived growth factor retains the complete multifunctionality of human norrin

doi: 10.1101/2025.10.15.682582

Figure Lengend Snippet: (A) Diagram illustrating TGF-ß1 and BMP-2 pathways. Norrin inhibits signaling via SMAD7 induction, thereby inhibiting pathway activation. (B) Noregen reduction in basal level and TGF-ß1 induced SMAD reporter activation. Values are means +/-SD; *P<0.05, **P<0.01, ***P<0.001. (C) ZO-1 immunostaining of HRMECs treated with TGF-ß1 or BMP-2 alone (translocation of ZO-1 to cytosol) or in combination with Noregen (restoration of ZO-1 at plasma membrane).

Article Snippet: The cells were weaned to media containing no hydrocortisone hemisuccinate prior to stimulation with Noregen or rh norrin (R&D Systems, Minneapolis MN;3014-NR).

Techniques: Activation Assay, Immunostaining, Translocation Assay, Clinical Proteomics, Membrane